{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:18:57Z","timestamp":1794406737026,"version":"4.9.0"},"reference-count":27,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,2,15]]},"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To report the efficacy, patient-reported, radiographic and safety outcomes of 4 years\u2019 certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RAPID-PsA (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01087788\">NCT01087788<\/jats:ext-link>) was double-blind and placebo-controlled to Week 24, dose-blind to Week 48 and open-label (OL) to Week 216. Patients were randomised 1:1:1 to either placebo or CZP 200\u2009mg every 2 weeks (Q2W) or 400\u2009mg every 4 weeks (Q4W) (following 400\u2009mg at Weeks 0\/2\/4). Patients randomised to CZP continued their assigned dose in the OL period. Patients randomised to placebo were re-randomised to CZP 200\u2009mg Q2W or 400\u2009mg Q4W (post-loading dose) at Week 16 (early escape) or after the double-blind phase. We present observed and imputed data; missing values were imputed using non-responder imputation (NRI) for categorical and last observation carried forward (LOCF) for continuous measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>409 patients were randomised; 20% (54\/273) of Week 0 patients randomised to CZP had prior anti-tumour necrosis factor (TNF) exposure; 67% (183\/273) completed 216 weeks. By Week 48, 60.4% of patients achieved Disease Activity Index for Psoriatic Arthritis low disease activity or remission, which was maintained; 66.3% achieved these outcomes at Week 216 (NRI). At Weeks 48 and 216, 39.2% of patients achieved minimal disease activity (NRI). 75% reduction in Psoriasis Area and Severity Index responses were 65% and 52% at Weeks 48 and 216 (NRI). Total resolution rates for enthesitis, dactylitis and nail psoriasis, at 4 years, were 71%, 81% and 65%, respectively (LOCF). Structural damage progression was low over 4 years\u2019 treatment. No new safety signals were identified after Week 96.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CZP efficacy in treating PsA was maintained over 4 years, in patients both with and without prior anti-TNF exposure, with no new safety signals identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2017-000582","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T08:40:17Z","timestamp":1521016817000},"page":"e000582","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct01087788","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01087788","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent\u2019s University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[{"name":"Centre for Prognosis Studies in the Rheumatic Diseases and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, New York Medical College, Metropolitan Hospital, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bauer","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Irvin-Sellers","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Khraishi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial University of Newfoundland, St John\u2019s, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Turkiewicz","sequence":"additional","affiliation":[{"name":"Rheumatology Associates Clinical Research Unit, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"additional","affiliation":[{"name":"Schoen Klinik, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"2025090312515642000_4.1.e000582.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201706"},{"key":"2025090312515642000_4.1.e000582.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312515642000_4.1.e000582.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"2025090312515642000_4.1.e000582.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/30.4.245"},{"key":"2025090312515642000_4.1.e000582.5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312515642000_4.1.e000582.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203697"},{"key":"2025090312515642000_4.1.e000582.7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000119"},{"key":"2025090312515642000_4.1.e000582.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312515642000_4.1.e000582.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030809"},{"issue":"Suppl 39","key":"2025090312515642000_4.1.e000582.10","first-page":"S142","article-title":"The assessment of disease activity and outcomes in psoriatic arthritis","volume":"23","author":"Kavanaugh","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312515642000_4.1.e000582.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.034165"},{"key":"2025090312515642000_4.1.e000582.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090312515642000_4.1.e000582.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"2025090312515642000_4.1.e000582.14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"2025090312515642000_4.1.e000582.15","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe","year":"1996","journal-title":"J Rheumatol"},{"key":"2025090312515642000_4.1.e000582.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq112"},{"key":"2025090312515642000_4.1.e000582.17","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"2025090312515642000_4.1.e000582.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006296"},{"key":"2025090312515642000_4.1.e000582.19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/2168479013514418","article-title":"The Role of Statistics in Regulatory Decision Making","volume":"48","author":"LaVange","year":"2014","journal-title":"Therapeutic Innovation & Regulatory Science"},{"key":"2025090312515642000_4.1.e000582.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312515642000_4.1.e000582.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312515642000_4.1.e000582.22","doi-asserted-by":"crossref","unstructured":"van Mens LJJ , van de Sande MGH , van Kuijk AWR , et al . Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 2018;77.doi:10.1136\/annrheumdis-2017-211998","DOI":"10.1136\/annrheumdis-2017-211998"},{"key":"2025090312515642000_4.1.e000582.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.008"},{"key":"2025090312515642000_4.1.e000582.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200387"},{"key":"2025090312515642000_4.1.e000582.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"2025090312515642000_4.1.e000582.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056457"},{"key":"2025090312515642000_4.1.e000582.27","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1136\/rmdopen-2017-000582corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:04Z","timestamp":1756929124000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,14]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/rmdopen-2017-000582"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000582","relation":{"correction":[{"id-type":"doi","id":"10.1136\/rmdopen-2017-000582corr1","asserted-by":"object"}],"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000582.supp1","asserted-by":"subject"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}